Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 587

1.

Testing two (of several) intravenous iron dosing strategies in hemodialysis.

Yu MK, Chertow GM.

Ann Transl Med. 2019 Jul;7(Suppl 3):S129. doi: 10.21037/atm.2019.05.75. No abstract available.

2.

Asymmetric dimethylarginine, erythropoietin resistance, and anemia in CKD.

Sirich TL, Chertow GM.

Ann Transl Med. 2019 Jul;7(Suppl 3):S86. doi: 10.21037/atm.2019.04.22. No abstract available.

3.

Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease.

Rhee JJ, Han J, Montez-Rath ME, Kim SH, Cullen MR, Stafford RS, Winkelmayer WC, Chertow GM.

J Diabetes Complications. 2019 Sep 3:107423. doi: 10.1016/j.jdiacomp.2019.107423. [Epub ahead of print]

PMID:
31537413
4.

Effects of Selonsertib in Patients with Diabetic Kidney Disease.

Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD; GS-US-223-1015 Investigators.

J Am Soc Nephrol. 2019 Oct;30(10):1980-1990. doi: 10.1681/ASN.2018121231. Epub 2019 Sep 10.

PMID:
31506292
5.

Modification of eGFR-Based CKD Definitions: Perfect, or Enemy of the Good?

Chertow GM, Beddhu S.

J Am Soc Nephrol. 2019 Oct;30(10):1807-1809. doi: 10.1681/ASN.2019070743. Epub 2019 Sep 10. No abstract available.

PMID:
31506290
6.

Estimated effects of early diuretic use in critical illness.

McCoy IE, Montez-Rath ME, Chertow GM, Chang TI.

Crit Care Explor. 2019 Jul;1(7). pii: e0021. doi: 10.1097/CCE.0000000000000021.

PMID:
31440746
7.

Prevalence of twenty-four hour urine testing in Veterans with urinary stone disease.

Ganesan C, Thomas IC, Song S, Sun AJ, Sohlberg EM, Kurella Tamura M, Chertow GM, Liao JC, Conti S, Elliott CS, Leppert JT, Pao AC.

PLoS One. 2019 Aug 8;14(8):e0220768. doi: 10.1371/journal.pone.0220768. eCollection 2019.

8.

Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.

Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, Chertow GM.

Kidney Int. 2019 Oct;96(4):1030-1036. doi: 10.1016/j.kint.2019.04.027. Epub 2019 May 16.

PMID:
31377056
9.

Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.

Toto RD, Goldenberg R, Chertow GM, Cain V, Stefánsson BV, Sjöström CD, Sartipy P.

J Diabetes Complications. 2019 Oct;33(10):107402. doi: 10.1016/j.jdiacomp.2019.06.007. Epub 2019 Jul 2.

PMID:
31375422
10.

Removing Disincentives to Kidney Donation: A Quantitative Analysis.

McCormick F, Held PJ, Chertow GM, Peters TG, Roberts JP.

J Am Soc Nephrol. 2019 Aug;30(8):1349-1357. doi: 10.1681/ASN.2019030242. Epub 2019 Jul 25. No abstract available.

PMID:
31345987
11.

Toward Greater Scrutiny of Dialysate Flow: Reply to the Letter to the Editor of Dr. Molano-Triviño and Colleagues.

Alvarez L, Leypoldt JK, Prichard S, Chertow GM.

Blood Purif. 2019 Jul 24:1-2. doi: 10.1159/000501842. [Epub ahead of print] No abstract available.

12.

Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.

Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T.

J Am Soc Nephrol. 2019 Aug;30(8):1523-1533. doi: 10.1681/ASN.2018121261. Epub 2019 Jul 19.

PMID:
31324734
13.

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients.

Cunningham J, Block GA, Chertow GM, Cooper K, Evenepoel P, Iles J, Sun Y, Ureña-Torres P, Bushinsky DA.

Kidney Int Rep. 2019 Apr 16;4(7):987-994. doi: 10.1016/j.ekir.2019.04.010. eCollection 2019 Jul.

14.

Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2-lessons from evolution, the animal kingdom and rare progeroid syndromes.

Stenvinkel P, Meyer CJ, Block GA, Chertow GM, Shiels PG.

Nephrol Dial Transplant. 2019 Jul 13. pii: gfz120. doi: 10.1093/ndt/gfz120. [Epub ahead of print]

PMID:
31302696
15.

A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.

Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M, Chertow GM.

J Am Soc Nephrol. 2019 Aug;30(8):1495-1504. doi: 10.1681/ASN.2018101016. Epub 2019 Jul 5.

PMID:
31278194
16.

Influence of prediabetes on the effects of intensive systolic blood pressure control on kidney events.

Rathi N, Whelton PK, Chertow GM, Cushman WC, Cheung AK, Wei G, Boucher R, Kimmel PL, Bress A, Kramer HJ, Al-Marji C, Greene T, Beddhu S.

Am J Hypertens. 2019 Jun 29. pii: hpz105. doi: 10.1093/ajh/hpz105. [Epub ahead of print]

PMID:
31257407
17.

Patterns of diuretic use in the intensive care unit.

McCoy IE, Chertow GM, Chang TI.

PLoS One. 2019 May 31;14(5):e0217911. doi: 10.1371/journal.pone.0217911. eCollection 2019.

18.

Defining a willingness-to-transplant threshold in an era of organ scarcity: Simultaneous liver-kidney transplant as a case example.

Cheng XS, Goldhaber-Fiebert J, Tan JC, Chertow GM, Kim WR, Wall AE.

Transplantation. 2019 May 15. doi: 10.1097/TP.0000000000002788. [Epub ahead of print]

PMID:
31107820
19.

Association of Hospitalization and Mortality Among Patients Initiating Dialysis With Hemodialysis Facility Ownership and Acquisitions.

Erickson KF, Zhao B, Niu J, Winkelmayer WC, Bhattacharya J, Chertow GM, Ho V.

JAMA Netw Open. 2019 May 3;2(5):e193987. doi: 10.1001/jamanetworkopen.2019.3987.

20.

Erratum.

Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA.

Nephrol Dial Transplant. 2019 May 15. pii: gfz111. doi: 10.1093/ndt/gfz111. [Epub ahead of print] No abstract available.

PMID:
31093680
21.

Challenges in Assessing the Burden of Hospitalized Heart Failure in End-Stage Kidney Disease.

Wang KM, Chertow GM.

J Card Fail. 2019 Jul;25(7):534-536. doi: 10.1016/j.cardfail.2019.05.001. Epub 2019 May 4. No abstract available.

PMID:
31063825
22.

Outcomes after left ventricular assist device implantation in patients with acute kidney injury.

Silver SA, Long J, Zheng Y, Goldstone AB, Franz D, Chang TI, Chertow GM.

J Thorac Cardiovasc Surg. 2019 Apr 4. pii: S0022-5223(19)30742-1. doi: 10.1016/j.jtcvs.2019.03.064. [Epub ahead of print]

PMID:
31053433
23.

Paying for Hemodialysis in Kerala, India: A Description of Household Financial Hardship in the Context of Medical Subsidy.

Bradshaw C, Gracious N, Narayanan R, Narayanan S, Safeer M, Nair GM, Murlidharan P, Sundaresan A, Retnaraj Santhi S, Prabhakaran D, Kurella Tamura M, Jha V, Chertow GM, Jeemon P, Anand S.

Kidney Int Rep. 2018 Dec 20;4(3):390-398. doi: 10.1016/j.ekir.2018.12.007. eCollection 2019 Mar.

24.

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.

Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M.

PLoS One. 2019 Mar 15;14(3):e0213774. doi: 10.1371/journal.pone.0213774. eCollection 2019.

25.

Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.

Byrd JB, Chertow GM, Bhalla V.

N Engl J Med. 2019 Apr 25;380(17):1589-1591. doi: 10.1056/NEJMp1901657. Epub 2019 Mar 13. No abstract available.

26.

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.

Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA.

Nephrol Dial Transplant. 2019 Mar 11. pii: gfz039. doi: 10.1093/ndt/gfz039. [Epub ahead of print] Erratum in: Nephrol Dial Transplant. 2019 May 15;:.

PMID:
30859218
27.

Treatment of metabolic acidosis with an intestinal binder.

Song S, Chertow GM.

Lancet. 2019 Apr 6;393(10179):1387-1388. doi: 10.1016/S0140-6736(19)30230-2. Epub 2019 Mar 8. No abstract available.

PMID:
30857645
28.

Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.

Block GA, Rosenbaum DP, Yan A, Chertow GM.

J Am Soc Nephrol. 2019 Apr;30(4):641-652. doi: 10.1681/ASN.2018080832. Epub 2019 Mar 7.

PMID:
30846557
29.

Updates in Management and Timing of Dialysis in Acute Kidney Injury.

Yu MK, Kamal F, Chertow GM.

J Hosp Med. 2019 Apr;14(4):232-238. doi: 10.12788/jhm.3105. Epub 2019 Feb 20. Review.

PMID:
30794134
30.

Relative sarcopenia and mortality and the modifying effects of chronic kidney disease and adiposity.

Ziolkowski SL, Long J, Baker JF, Chertow GM, Leonard MB.

J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):338-346. doi: 10.1002/jcsm.12396. Epub 2019 Feb 19.

31.

Chronic Kidney Disease and the Adiposity Paradox: Valid or Confounded?

Ziolkowski SL, Long J, Baker JF, Chertow GM, Leonard MB.

J Ren Nutr. 2019 Jan 29. pii: S1051-2276(18)30283-8. doi: 10.1053/j.jrn.2018.11.011. [Epub ahead of print]

PMID:
30709713
32.

Differential Molecular Modeling Predictions of Mid and Conventional Dialysate Flows.

Leypoldt JK, Prichard S, Chertow GM, Alvarez L.

Blood Purif. 2019;47(4):369-376. doi: 10.1159/000495022. Epub 2019 Jan 30.

PMID:
30699416
33.

Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population.

Gilbertson DT, Rothman KJ, Chertow GM, Bradbury BD, Brookhart MA, Liu J, Winkelmayer WC, Stürmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB.

J Am Soc Nephrol. 2019 Feb;30(2):346-353. doi: 10.1681/ASN.2018060581. Epub 2019 Jan 24.

PMID:
30679380
34.

Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis.

Schwantes-An TH, Liu S, Stedman M, Decker BS, Wetherill L, Edenberg HJ, Vatta M, Foroud TM, Chertow GM, Moe SM.

Am J Nephrol. 2019;49(2):125-132. doi: 10.1159/000496060. Epub 2019 Jan 22.

PMID:
30669147
35.

Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with End-stage Kidney Disease Receiving Maintenance Hemodialysis.

Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE 3rd, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD.

Clin J Am Soc Nephrol. 2019 Jan 21. pii: CJN.06190518. doi: 10.2215/CJN.06190518. [Epub ahead of print]

PMID:
30665924
36.

Market Consolidation and Mortality in Patients Initiating Hemodialysis.

Erickson KF, Winkelmayer WC, Ho V, Bhattacharya J, Chertow GM.

Value Health. 2019 Jan;22(1):69-76. doi: 10.1016/j.jval.2018.06.008. Epub 2018 Jul 27.

PMID:
30661636
37.

Prospective Biopsy-Based Study of Chronic Kidney Disease of Unknown Etiology in Sri Lanka.

Anand S, Montez-Rath ME, Adasooriya D, Ratnatunga N, Kambham N, Wazil A, Wijetunge S, Badurdeen Z, Ratnayake C, Karunasena N, Schensul SL, Valhos P, Haider L, Bhalla V, Levin A, Wise PH, Chertow GM, Barry M, Fire AZ, Nanayakkara N.

Clin J Am Soc Nephrol. 2019 Jan 18. pii: CJN.07430618. doi: 10.2215/CJN.07430618. [Epub ahead of print]

PMID:
30659059
38.

Prior Hospitalization Burden and the Relatedness of 30-Day Readmissions in Patients Receiving Hemodialysis.

Lin E, Bhattacharya J, Chertow GM.

J Am Soc Nephrol. 2019 Feb;30(2):323-335. doi: 10.1681/ASN.2018080858. Epub 2019 Jan 3.

PMID:
30606782
39.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

PMID:
30578152
40.

Randomized trial of intravenous iron-induced hypophosphatemia.

Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W.

JCI Insight. 2018 Dec 6;3(23). pii: 124486. doi: 10.1172/jci.insight.124486.

41.

Would government compensation of living kidney donors exploit the poor? An empirical analysis.

Held PJ, McCormick F, Chertow GM, Peters TG, Roberts JP.

PLoS One. 2018 Nov 28;13(11):e0205655. doi: 10.1371/journal.pone.0205655. eCollection 2018.

42.

PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.

Ginsberg C, Craven TE, Chonchol MB, Cheung AK, Sarnak MJ, Ambrosius WT, Killeen AA, Raphael KL, Bhatt UY, Chen J, Chertow GM, Freedman BI, Oparil S, Papademetriou V, Wall BM, Wright CB, Ix JH, Shlipak MG; SPRINT Research Group.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1816-1824. doi: 10.2215/CJN.05390518. Epub 2018 Nov 13.

PMID:
30425104
43.

The Terrible Toll of the Kidney Shortage.

McCormick F, Held PJ, Chertow GM.

J Am Soc Nephrol. 2018 Dec;29(12):2775-2776. doi: 10.1681/ASN.2018101030. Epub 2018 Nov 12. No abstract available.

PMID:
30420419
44.

Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.

Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, Neylan JF, Chertow GM.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1115-1124. doi: 10.1093/ndt/gfy318.

45.

Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.

Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, Cutler J, Fine L, Boucher R, Wei G, Zhang C, Kramer H, Bress AP, Kimmel PL, Oparil S, Lewis CE, Rahman M, Cushman WC.

J Am Heart Assoc. 2018 Sep 18;7(18):e009326. doi: 10.1161/JAHA.118.009326.

46.

Payer Type, Race/Ethnicity, and the Timing of Surgical Management of Urinary Stone Disease.

Brubaker WD, Dallas KB, Elliott CS, Pao AC, Chertow GM, Leppert JT, Conti SL.

J Endourol. 2019 Feb;33(2):152-158. doi: 10.1089/end.2018.0614. Epub 2018 Nov 16.

PMID:
30343603
47.

Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?

Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Riessen E, Shapiro B, Stergiou GS, Tsioufis K, Whelton PK, Whittle J, Wright JT, Papademetriou V.

J Clin Hypertens (Greenwich). 2018 Nov;20(11):1644-1645. doi: 10.1111/jch.13395. Epub 2018 Oct 17. No abstract available.

48.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P.

J Diabetes Complications. 2018 Dec;32(12):1113-1117. doi: 10.1016/j.jdiacomp.2018.09.005. Epub 2018 Sep 13.

49.

Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants.

Supiano MA, Lovato L, Ambrosius WT, Bates J, Beddhu S, Drawz P, Dwyer JP, Hamburg NM, Kitzman D, Lash J, Lustigova E, Miracle CM, Oparil S, Raj DS, Weiner DE, Taylor A, Vita JA, Yunis R, Chertow GM, Chonchol M.

PLoS One. 2018 Sep 26;13(9):e0203305. doi: 10.1371/journal.pone.0203305. eCollection 2018.

50.

Patient-Reported Experiences of Dialysis Care Within a National Pay-for-Performance System.

Brady BM, Zhao B, Niu J, Winkelmayer WC, Milstein A, Chertow GM, Erickson KF.

JAMA Intern Med. 2018 Oct 1;178(10):1358-1367. doi: 10.1001/jamainternmed.2018.3756.

Supplemental Content

Loading ...
Support Center